



Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/696,862
	Filing Date	October 30, 2003
	First Named Inventor	Jingrong Cao
	Group Art Unit	1624
	Examiner Name	Venkataram Balasubramanian
	Attorney Docket Number	VPI/02-115 US

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
M	C1	Hoshino et al., "Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors," <i>Oncogene</i> , 18:813-22 (1999).
M	C2	Frey et al., "TGF-beta regulation of mitogen-activated protein kinases in human breast cancer cells," <i>Cancer Letters</i> , 117(1):41-50 (1997).
M	C3	Putz et al., "Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines," <i>Cancer Research</i> , 59(1):227-33 (1999).
M	C4	Kortylewski et al., "Mitogen-activated protein kinases control p27/Kip1 expression and growth of human melanoma cells," <i>Biochemical Journal</i> , 357(Pt 1):297-303 (2001).
M	C5	Hirooka et al., "Therapeutic potential of Rho-kinase inhibitors in cardiovascular diseases," <i>Am. J. Cardiovasc Drugs</i> , 5(1): 31-39 (2005).
M	C6	Mueller et al., "RHO kinase, a promising drug target for neurological disorders," <i>Nature Reviews, Drug Discovery</i> , 4:387-398 (2005).
M	C7	Doble et al., "GSK-3: tricks of the trade for a multi-tasking kinase," <i>Journal of Cell Science</i> , 116:1175-1186 (2003).
M	C8	Chang et al., "Role of cAMP-dependent pathway in eosinophil apoptosis and survival," <i>Cell. Immunology</i> , 203(1):29-38 (2000).
M	C9	Plotkin et al., "Insulin mimetic action of synthetic phosphorylated peptide inhibitors of glycogen synthase kinase-3," <i>J. Pharm. Exp. Ther.</i> 305:974-980 (2003).

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature V. Balasubramanian	Date Considered 2/9/06
---	----------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.